Guanhao Biotech

GuanhaoBio is a high-tech enterprise based in the regenerative medicine industry, expanding into life health-related fields, and integrating global high-end technology resources and achievements. It continuously deploys business in the fields of biomaterials, cell/stem cell, pharmaceuticals, as well as advanced medical technologies and products, forming a core business structure of "3+1," namely three major business sectors—materials, cells, pharmaceuticals—and one technology incubation platform. In the field of regenerative materials, after more than a decade of development, the company has established an animal-derived biomaterials technology platform with international competitiveness. Relying on its leading position in the research and development of new biomaterials with induced regeneration functions and related products, the company has undertaken more than 20 national and local scientific research projects. It has become a research and development center and industrialization demonstration base in this industry sector. The "National Engineering Laboratory for Regenerative Medical Implant Devices" and the "High-Tech Industrialization Demonstration Project for Regenerative Biological Membranes," both initiated by the National Development and Reform Commission, have successively settled in GuanhaoBio. Currently, the company owns more than a hundred patents at home and abroad. Its independently developed and marketed products include: Bio-type hard brain (spinal) membrane patches, Type B hard brain membrane patches, thoracic and general surgery repair membranes (B/P), sterile biological wound protection membranes, Airui'ou breast patches, Yudeqing decellularized corneal grafts; as well as intraocular lens products represented by Zhuhai Xiangle, which can be widely used in neurosurgery, thoracic and general surgery, ophthalmology, dermatology, orthopedics, plastic surgery, and other fields.In the field of cells/stem cells, the company currently engages in autologous cartilage tissue cell transplantation technology and immune cell storage technology, and it is continuously deploying in the research and development of immune cell therapy technology. In the stem cell field, the company collaborates with Peking University and Professor Hongkui Deng's team to establish the Beihao Stem Cell and Regenerative Medicine Research Institute. This institute will build a world-class common key technology platform for immune cells, gather some of the world’s most advanced talents and technologies, and conduct stem cell and clinical translational research.